Abbvie to submit first Genmab collaboration candidate in 2022
According to Genmab-partner Abbvie, the two companies are close to filing for marketing approval for epcoritamab, a potential treatment for lymphoma.
by andreas lønstrup, translated by daniel pedersen
Genmab and its partner, Abbvie, will soon be ready to submit epcoritamab for marketing authorization as a treatment of the cancer type diffuse large B-cell lymphoma (DLCBL)
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novartis increases sales of Genmab-developed sclerosis drug
For subscribers
FDA fast-tracks Abbvie's lung cancer drug
For subscribers
